Citius Pharmaceuticals To Host Investor Call On Monday, June 3, 2024 At 8:30 AM ET To Discuss Topline Results Of Phase 3 Trial Of Mino-Lok Antibiotic Lock Solution

5/29/24 8:47:32 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CTXR alert in real time by email

Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET

CRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution.

Get the next $CTXR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CTXR

Date	Price Target	Rating	Analyst
1/18/2022	$4.00 → $6.00	Buy	HC Wainwright & Co.
11/30/2021	$4.00	Buy	Maxim Group

More analyst ratings

$CTXR
Press Releases

Fastest customizable press release news feed in the world

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
CRANFORD, N.J., Nov. 22, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR) announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 ("Reverse Stock Split"). Pursuant to the laws of the State of Nevada and subject to prior approval by the Company's Board of Directors, Citius Pharma was not required to obtain shareholder approval to effectuate the Reverse Stock Split. The Reverse Stock Split will become effective at 5:00 pm Eastern Time on November 25, 2024. The Company's common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis beginning
11/22/24 9:00:00 AM ET
$CTXR
Biotechnology: Pharmaceutical Preparations
Health Care
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
CRANFORD, N.J., Nov. 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today closed its previously announced registered direct offering for the purchase of an aggregate of 12,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,000,000 shares of its common stock, at a purchase price of $0.25 per share and accompanying warrant. The warrants have an exercise price of $0.25 per share, are exercisable immediately upon issuance, and expire five years from the initial exercise date.
11/18/24 4:05:00 PM ET
$CTXR
Biotechnology: Pharmaceutical Preparations
Health Care
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
CRANFORD, N.J., Nov. 15, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 12,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,000,000 shares of its common stock, at a purchase price of $0.25 per share and accompanying warrant in a registered direct offering. The warrants will have an exercise price of $0.25 per share, will be exercisable immediately upon issuance, and will expir
11/15/24 1:30:00 PM ET
$CTXR
Biotechnology: Pharmaceutical Preparations
Health Care

$CTXR
Financials

Live finance-specific insights

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion. Conference Call Details: Date: Tuesday, August 13, 2024 Time: 8:30 a.m. Eastern Time Dial In: 1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international) Webcast: Register for the webcast here. A replay will
8/12/24 8:00:00 AM ET
$CTXR
Biotechnology: Pharmaceutical Preparations
Health Care
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related blood
5/29/24 8:30:00 AM ET
$CTXR
Biotechnology: Pharmaceutical Preparations
Health Care
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update
$41.7 million in cash and cash equivalents as of September 30, 2022; extends runway through December 2023 Mino-Lok® Phase 3 trial closer to completion with 169 patients recruited, 72 failure events and 17 patients in active treatment or pending data review I/ONTAK BLA accepted for filing by the FDA; updated PDUFA target action date is July 28, 2023 Halo-Lido Phase 2b trial progressed; data readout expected 2H 2023 Multiple value-driving catalysts anticipated in 2023, including a potential drug approval and two trial completions CRANFORD, N.J., Dec. 22, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated
12/22/22 4:30:00 PM ET
$CTXR
Biotechnology: Pharmaceutical Preparations
Health Care

Citius Pharmaceuticals To Host Investor Call On Monday, June 3, 2024 At 8:30 AM ET To Discuss Topline Results Of Phase 3 Trial Of Mino-Lok Antibiotic Lock Solution

Chat with this insight

Recent Analyst Ratings for $CTXR

$CTXR Press Releases

Fastest customizable press release news feed in the world

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

$CTXR Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Citius Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G filed by Citius Pharmaceuticals Inc.

SEC Form SC 13G filed by Citius Pharmaceuticals Inc.

$CTXR Market Insights

Live Market Insights

EF Hutton Initiates Coverage On Citius Pharma with Buy Rating, Announces Price Target of $6

Citius Pharmaceuticals announced expected milestones in H2 2024.

Citius Pharmaceuticals Reports Expected Milestones

$CTXR Leadership Updates

Live Leadership Updates

$CTXR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$CTXR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$CTXR SEC Filings

Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls

Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

HC Wainwright & Co. reiterated coverage on Citius Pharmaceuticals with a new price target

Maxim Group initiated coverage on Citius Pharmaceuticals with a new price target

HC Wainwright resumed coverage on Citius Pharmaceuticals

SEC Form 4 filed by Director Webb Carol

SEC Form 4 filed by Director Dutia Suren G

SEC Form 4 filed by Vice Chairman Holubiak Myron Z

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SEC Form 424B5 filed by Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$CTXR Financials

Live finance-specific insights

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update

Recent Analyst Ratings for
$CTXR

$CTXR
Press Releases

$CTXR
Large Ownership Changes

$CTXR
Market Insights

$CTXR
Leadership Updates

$CTXR
Analyst Ratings

$CTXR
Insider Trading

$CTXR
SEC Filings

$CTXR
Financials